EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 17396258.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
(32)P phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom (32)P is the most optimal treatment option, an assertion supported by two large studies with long follow-up. The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for (32)P phosphate therapy.
Medical subject headings
- Myeloproliferative Disorders
- Phosphorus Radioisotopes
- Radiotherapy
- Thrombocythemia, Essential